|
May 24
|
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
May 15
|
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
|
|
May 14
|
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
|
|
May 6
|
aTyr Pharma to Present at Upcoming Investor Conferences
|
|
May 2
|
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
|
|
Apr 21
|
aTyr Pharma Insiders Placed Bullish Bets Worth US$514.6k
|
|
Apr 1
|
aTyr Pharma to Participate in April Investor Conferences
|
|
Mar 26
|
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition
|
|
Mar 16
|
aTyr Pharma Full Year 2023 Earnings: Revenues Disappoint
|
|
Mar 15
|
aTyr Pharma, Inc. (NASDAQ:LIFE) Q4 2023 Earnings Call Transcript
|
|
Mar 15
|
Q4 2023 aTyr Pharma Inc Earnings Call
|
|
Mar 15
|
aTyr Pharma Inc (LIFE) Reports Full Year 2023 Financial Results and Corporate Progress
|
|
Mar 14
|
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
|